Amid New M&A Rumors, Amarin CEO Focused On Vascepa Approval
Pfizer and Gilead Seen As Suitors
Executive SummaryJohn Thero insists company is focused on approval and launch, as interest in European rights grow.
You may also be interested in...
The addressable patient population in the US could increase by 4.5 million if new trial is successful.
Janssen’s hemato-oncology success rolls on with impressive new overall survival data
While the BCMA-targeting CAR-T competition is grabbing attention, bluebird has good news in sickle cell therapy.